Nuevas estrategias en terapia antitumoral basadas en la inducción de la apoptosis
227
10.
Satyam, A.; Hocker. MD.; Kane-‐Maguire, KA.; Morgan, AS.; Villar, HO.; Lyttle, MH. (1996)
Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-‐
transferase. J Med Chem 39(8), 1736-‐1747.
11.
Lyttle, MH.; Satyam, A.; Hocker, MD.; et al. (1994) Glutathione-‐Stransferase activates novel
alkylating agents. J Med Chem 37(10), 1501-‐1507.
12.
Thévenin, AF.; Zony, CL.; Bahnson, BJ.; Colman, RF. (2011) GSTpi modulates JNK activity
through a direct interaction with JNK substrate, ATF2. Protein Sci 20(5), 834-‐848.
13.
Vergotea, I.; Finklerb, N.; Del Campoc. J. et al. (2009) Phase 3 randomised study of
canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan
as third-‐line therapy in patients with platinum-‐refractory or –resistant ovarian cancer.
Eur J Cancer 45, 2324-‐2332.
14.
Turella, P.; Filomeni, G.; Dupuis, ML. et al. (2006) A strong glutathione S-‐transferase
inhibitor overcomes the p-‐glycoproteinmediated resistance in tumour cells. 6-‐(7-‐nitro-‐
2,1,3-‐benzoxadiazol-‐4-‐ylthio)hexanol (NBDHEX) triggers a caspasedependent apoptosis
in MDR1-‐expressing leukemia cells. J Biol Chem 281, 23725-‐23732.
15.
Filomeni, G.; Turella, P.; Dupuis, ML. et al. (2008) 6-‐(7-‐nitro-‐2, 1, 3-‐benzoxadiazol-‐4-‐
ylthio)hexanol, a specific glutathione Stransferase inhibitor, overcomes the multidrug
resistance (MDR)-‐associated protein 1-‐mediated MDR in small cell lung cancer. Mol
Cancer Ther 7, 371-‐379.
16.
Pellizzari Tregno, F.; Sau, A.; Pezzola, S. et al. (2009) In vitro and in vivo efficacy of 6-‐(7-‐
nitro-‐2, 1, 3-‐benzoxadiazol-‐4-‐ylthio)hexanol (NBDHEX) on human melanoma. Eur J
Cancer 45, 2606-‐2617.
17.
Tentori, L.; Dorio, AS.; Mazzon, E.; Muzi, A.; Sau, A.; Cuzzocrea, S. et al. (2011) The
glutathione transferase inhibitor 6-‐(7-‐nitro-‐2,1,3-‐benzoxadiazol-‐4-‐ylthio)hexanol
(NBDHEX) increases temozolomide efficacy against malignant melanoma. Eur J Cancer 45,
1219-‐1230.
18.
Huang, S.; Shu, L.; Easton, J. et al. (2004) Inhibition of Mammalian Target of Rapamycin
Activates Apoptosis Signal-‐regulating Kinase 1 Signaling by Suppressing Protein
Phosphatase 5 Activity. J Biol Chem 279(35), 36490-‐36496.
19.
Temkin, SM.; Yamada, SD.; Fleming, GF. (2010) A phase I study of weekly temsirolimus
and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.
Gynecol Oncol 117, 473-‐476.
20.
Yap, TA.; Garrett
1, MD.;
Walton, MI.; Raynaud, F.; De Bono, JS.; Workman, P. (2008)
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises. Curr Opin in
Pharmacol 8, 393-‐412.
21.
Strimpakos, AS.; Karapanagiotou, EM.; Saif, MW.; Syrigos, KN. (2009) The role of mTOR in
the management of solid tumors: An overview. Cancer Treat Rev; 35:148-‐159.
22.
Ciardiello F. (2005) Epidermal growth factor receptor inhibitors in cancer treatment.
Future Oncol 1(2), 221-‐234.
23.
Salomon, DS.; Brandt, R.; Ciardiello, F. et al. (1995) Epidermal growth factorrelated
peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol 19, 183-‐232.
24.
Dummer Meira, D.; Nóbrega, I.; De Almeida, VH.; Mororo, JS.; Cardoso, AM.; Silva, R. (2009)
Different antiproliferative effects of matuzumab and cetuximab in A431 cells are
associated with persistent activity of the MAPK pathway. Eur J Cancer 45, 1265-‐1273.
25.
Oh, IJ.; Jung-‐Ban, H.; Kim, KS.; Kim, YC. (2012) Retreatment of gefitinib in patients with
non-‐small-‐cell lung cancer who previously controlled to gefitinib: A single-‐arm, open-‐label,
phase II study. Lung Cancer 77, 121-‐127.
26.
Chang, SC.; Chang, CY.; Chang, SJ.; Yuan, MK.; Lai, YC.; Liu, YC. (2013) Gefitinib-‐Related
Interstitial Lung Disease in Taiwanese Patients With Non–Small-‐Cell Lung Cancer. Clin
Lung Cancer 14(1), 55-‐61.
